Upstream Bio, Inc. (UPB) has received a new Buy rating, initiated by TD Cowen analyst, Yaron Werber. Yaron Werber has given his Buy rating due ...

Tessa Romero, an analyst from J.P. Morgan, has initiated a new Buy rating on Upstream Bio, Inc. (UPB). Tessa Romero’s rating is based on ...

Upstream Bio garners analyst optimism for its lead drug verekitug, which could disrupt the $7.5 billion asthma biologics ...

Multiple players are exploring whether modalities designed to combat B cell malignancies can be repurposed against lupus, myasthenia gravis and other conditions traced to misdirected immune response.

Not only are deals going off at higher valuations than the companies initially anticipated, but the prices have been popping after the stocks began trading in the public markets. Observers are hoping ...

Septerna's protracted initial public offering (IPO) on the Nasdaq has finally reached its conclusion, with the final amount ...

These are independent reviews of the products mentioned, but TIME receives a commission when purchases are made through ...

COURTESY STATE DEPARTMENT OF LAND AND NATURAL RESOURCES Debris from upstream has flowed into the ocean entrance of the Ala Wai Canal and its harbor. Question : Auwe ! Saturday was a shocking day at ...

(Reuters) -Goldman Sachs-backed drug developer Septerna said on Thursday it was seeking a valuation of $743.1 million in its upsized initial public offering in the United States, a sign of upbeat ...

A team of divers will be conducting survey work in the Iowa River on the University of Iowa campus on Oct. 22—25. This work ...

Upstream Bio Inc. (NASDAQ: UPB) also had an IPO and raised $293 million. The clinical-stage biotechnology company develops treatments for inflammatory diseases, with an initial focus on severe ...

OrbiMed Advisors LLC, a prominent shareholder in Upstream Bio, Inc. (NASDAQ:UPB), recently acquired a significant amount of the company's common stock, according to a filing with the Securities and ...